Using the results of Phase III studies in clinical practice depends on how representative study participants are of the clinical population to whom the results will be applied. The closer the characteristics between the subgroup who participate in a clinical trial and the whole population, the easier it is for clinicians to apply the results directly to the patient that he/she is treating. Trial participation is generally more happenstance than a systematic sampling of a population and is limited by eligibility criteria that do not reflect the entire clinical population. Phase III study populations tend to be younger with fewer comorbidities and not represent the gender and ethnicity of the target population, limiting generalizability of results. When moving from Phase III studies to Phase IV postmarketing studies, there will be differences in the populations prescribed the medications and the outcomes achieved, highlighting the gap between gold-standard evidence from Phase III randomized studies and the application of that evidence in real-world practice. Palliative care services are referral based, yet there are no standard national or international referral criteria. As such, the populations served by specialist palliative care services are ill defined, complicating the problem of defining a "representative" population even further. Key characteristics have been suggested to aid generalizability of research findings in palliative care, although these are poorly reported. In palliative care, large-scale Phase III, symptom control effectiveness studies are being conducted successfully. This includes the work of the Australian National Cancer Symptom Trials (CST) group. Can the findings from these studies be generalized to the broader palliative cancer care population in the same health system? The aim of this analysis was to compare key demographic factors between participants with cancer in these Phase III studies and people referred to nontrial specialist palliative care services using standard prospective data collection. The null hypothesis was that there was no difference between participants' characteristics. Keywords national, cancer, symptom, trials, comparability, (cst), australian, group's, study, populations, referrals, noncst, specialist, palliative, care, services, participating, outcomes, collaboration to assess the accuracy of SCORTEN in predicting inhospital mortality. These studies overall have shown that the SCORTEN performance during the first five days of hospitalization was excellent and is best on Day 3. 4 The most recent accuracy study was a retrospective study that included adult and pediatric patients admitted to a burn center with biopsyconfirmed SJS/TEN. SCORTEN scores were calculated on Day 1 and Day 3 of hospital admission, and they compared predicted with actual mortality in these patients. This study, however, claims that the accuracy of the SCORETEN model remains unclear and could be more precise, therefore encouraging future studies to explore other variables and a possible reformulated SCORTEN.
to assess the accuracy of SCORTEN in predicting inhospital mortality. These studies overall have shown that the SCORTEN performance during the first five days of hospitalization was excellent and is best on Day 3. 4 The most recent accuracy study was a retrospective study that included adult and pediatric patients admitted to a burn center with biopsyconfirmed SJS/TEN. SCORTEN scores were calculated on Day 1 and Day 3 of hospital admission, and they compared predicted with actual mortality in these patients. This study, however, claims that the accuracy of the SCORETEN model remains unclear and could be more precise, therefore encouraging future studies to explore other variables and a possible reformulated SCORTEN. 5 These studies exemplify that like many things in medicine, mortality probability models cannot 100% predict outcomes in individual patients.
That said, the presence of palliative medicine is increasing in ICU settings, and there is an increasing need for prognostic tools and evidence-based practice to help facilitate GOC discussion. In support of the traditional palliative care philosophy, recent findings show that aggressive end-of-life care does not correlate with improved perception of the medical care received near time of death and that many patients near the end of life often prefer palliative treatments over aggressive life-extending therapies. 6 Because the SCORTEN assessment was available and done quickly, we were able to present this patient's family members with an accurate prognostication of their loved one's in-hospital mortality. With these data, we were able to have a more direct GOC discussion, and the patient was able to die with care in accordance with her wishes.
This case study and discussion demonstrates the acuity of decision making necessary in a patient with severe integument injury with a >90% in-hospital mortality likelihood. It additionally provides palliative care providers with the knowledge of the SCORTEN illness severity and in-hospital mortality scale, demonstrating how having such a tool can aid in expediting GOC discussions, leading to improved patient end-oflife care. 
Introduction
Using the results of Phase III studies in clinical practice depends on how representative study participants are of the clinical population to whom the results will be applied. The closer the characteristics between the subgroup who participate in a clinical trial and the whole population, the easier it is for clinicians to apply the results directly to the patient that he/she is treating. Trial participation is generally more happenstance than a systematic sampling of a population and is limited by eligibility criteria that do not reflect the entire clinical population. 1 Phase III study populations tend to be younger with fewer comorbidities and not represent the gender and ethnicity of the target population, limiting generalizability of results.
1,2 When moving from Phase III studies to Phase IV postmarketing studies, there will be differences in the populations prescribed the medications and the outcomes achieved, 3 highlighting the gap between gold-standard evidence from Phase III randomized studies and the application of that evidence in real-world practice. Palliative care services are referral based, yet there are no standard national or international referral criteria. As such, the populations served by specialist palliative care services are ill defined, complicating the problem of defining a ''representative'' population even further. Key characteristics have been suggested to aid generalizability of research findings in palliative care, 4 although these are poorly reported.
In palliative care, large-scale Phase III, symptom control effectiveness studies are being conducted successfully. This includes the work of the Australian National Cancer Symptom Trials (CST) group.
5e10 Can the findings from these studies be generalized to the broader palliative cancer care population in the same health system?
The aim of this analysis was to compare key demographic factors between participants with cancer in these Phase III studies and people referred to nontrial specialist palliative care services using standard prospective data collection. The null hypothesis was that there was no difference between participants' characteristics.
Methods and Analysis
This is a comparison of two independent but complementary consecutive cohorts generated contemporaneously through clinical trials and clinical quality initiatives nationally in Australia. This study compared age, sex, cancer diagnosis, language, socioeconomic status (using the Index of Relative Advantage and 
Statistical Considerations
Demographic data were summarized using counts, percentages, medians, and interquartile ranges.
Median ages and functional status were compared using the Wilcoxon rank sum test, whereas differences between the distribution of gender, language, and socioeconomic status were compared using Pearson's chi-squared test. Analyses were performed using R (Version 3.4.0, 2017; Auckland, New Zealand). No missing data were imputed. This study is reported using the STROBE framework for observational studies. 13 Anonymized, deidentified data in secondary analysis required no further ethical review. Primary data collection was covered by relevant Human Research Ethics Committees.
Results
Nine hundred two people with cancer participated in six Phase III placebo-controlled, randomized controlled trials across 17 sites (Table 1) . A consecutive cohort of 75,240 patients with a cancer diagnosis seen in 117 non-CST sites were the comparator population.
The CST cohort were younger (median age 71 [interquartile range {IQR} 62e79]) than the PCOC population (median 73 [IQR 63e81]; P ¼ 0.003). There was no difference in sex between the groups (56.1% male in CST; 54.8% PCOC; P ¼ 0.483), but the CST cohort had a higher proportion of English speakers (CST 95.0%; PCOC 92.2%; P ¼ 0.004). The most frequent four diagnoses in the CST cohort were as follows: lung, colorectal, gynecological, and prostate cancers. For PCOC, this was as follows: lung, colorectal, other gastrointestinal tract, and breast cancers ( Table 2) . Functional status, unlike the parameters reported in Table 3 , changes over time in life-limiting illnesses so the decision was made to report the first Australianmodified Karnofsky Performance Status in each database for each person. The studies on delirium and inoperable malignant bowel obstruction tended to be later in people's clinical course, while studies on breathlessness tended to be in people with better levels of function (Table 3) . Overall, people in CST studies tended to have a better level of function with a median score of 60 (IQR 50e70) than people referred to PCOC (median 50 [IQR 30e60]; P < 0.001). Service delivery models were similar between the cohorts (Table 4) .
Patients referred to PCOC are more likely to have a higher socioeconomic status than the general Australian population. The highest two Index of Relative Advantage and Disadvantage quintiles are overrepresented in both cohorts, with this being even greater in CST (52.1%; PCOC 49.0%; P ¼ 0.022).
Discussion
This study found demographic differences between a Phase III study cohort and the general palliative care population consistent with differences described in other clinical specialties. Despite these statistical differences, the findings of these Phase III studies are likely to be able to be applied to the broader palliative care population.
Differences in cancer diagnoses almost certainly reflect the symptoms explored: breathlessness and anorexia are both prevalent in lung cancer 5, 6 ; bowel obstruction is prevalent in gynecological cancers 9 ; and pain is frequently encountered in late-stage metastatic breast and prostate cancers. 8 In efficacy studies that have the most stringent eligibility criteria, the population is likely to be healthier with fewer comorbidities, often reflecting only the index clinical presentation. By contrast, effectiveness studies have broader eligibility criteria, more closely reflecting day-to-day practice. This study demonstrates that for the criteria compared, CST studies are effectiveness studies maximizing their generalizability. Age difference between groups: P ¼ 0.003. b 16 (0.02%) missing PCOC; 14 (1.6%) missing CST: P ¼ 0.483 for between-group comparison. c 1343 (1.8%) missing PCOC; 87 (9.6%) missing CST; P ¼ 0.004 for between-group comparison. In palliative care, a framework for classifying research subpopulations to which the research findings are being applied by clinicians, health planners, and funders in real-world settings has been suggested.
14 Existing literature often inadequately describes the characteristics of patients, limiting the utility of results. Hjermstad et al. identified wide variation in palliative care services and patients. 15 Patients' characteristics differed when compared across predefined categories of participating centers.
Detailed characterization is the first step in improving use of palliative care research. Palliative care cancer populations are inconsistently and insufficiently described when reporting randomized controlled trials requiring investigators to improve this aspect of trial reporting. 
Limitations
The data from the PCOC cohort do not contain comorbidity data, and the research database has comorbidities only relevant to each individual study. Stage of disease was also not available. Future work in this area should collect such data prospectively.
Strengths
All data in this data set were generated prospectively with high levels of completeness. The use of the data in this secondary analysis is directly in keeping with the purposes for which the data were collected.
Clinical Implications
The CST has run effectiveness studies with the widest possible eligibility criteria to ensure that the generalizability of the findings is maximized. The findings in this study are that the CST cohort largely mirrors the palliative care population that we serve. This gives confidence for clinicians to explore applying the findings from these studies to their own setting, as many have done given demonstrated changes in practice. 19, 20 Research Implications
Continuing to refine the evidence base for therapeutic interventions in palliative care is paramount if we are to realize the vision to personalize care. Palliative care Phase II and III studies need to be effectiveness studies built on the broadest possible population of palliative care patients. Dear Editor: I read the recent paper regarding death rattle treatment with great interest. 1 The authors are commended for giving consideration to this naturally occurring patient noise that is distressing to clinicians and families.
Clinicians have largely believed there is no patient distress as death rattle develops in the context of declining consciousness. We established that there is no patient distress associated with the development
